BioAdaptives’ LungFlute Marketing Agreement and New

Related Articles

Las Vegas, Nevada, December 15, 2021 (GLOBE NEWSWIRE) – via New Media Wire – BioAdaptives, Inc. (OTCMkts: BDPT) that it has entered into a marketing agreement with Acoustic Innovations LLC, developer of the medical device LungFlute™ OscPEP (Positive Expiratory Pressure Swings). LungFlute™ is an FDA-approved medical device, with proven health benefits related to improving lung hygiene and function, as well as facilitating the diagnosis of lung disease. The agreement of the parties provides BioAdaptives with marketing rights to LungFlute™ in the United States and Canada as well as other countries in which the device is registered and approved for sale. Currently, LungFlute™ is supported by several clinical studies and approved for sale in China, Australia, the European Union, and most of Asia.

The patented LungFlute™ produces low-frequency sonic energy that breaks up viscous mucus secretions and stimulates the ciliary system to safely eliminate germs and other harmful substances trapped deep in the lungs.

Edward Jacobs, CEO of BioAdaptives, Inc. The LungFlute is an OscPEP device that is easy to use and safe for children and adults. Because of its proven diagnostic value in increasing production of critical sputum samples, LungFlute™ is positioned to play a central role in the Greater Tuberculosis (TB) trial in Africa, which costs $800,000 We expect LungFlute™ to contribute significantly to the success of this trial by significantly increasing the number of TB cases identified for treatment.

“BioAdaptives intends to market the LungFlute™ device, re-engineered as LungCleanser™, along with PrimiLungs™ natural antiviral and anti-inflammatory formula as part of the new LungArmor™ package. Routine use of this combination is designed to promote healthy, strong lungs and effortless breathing by improving Lung cleanliness and enhanced immune defense of the lungs.

About BioAdaptives, Inc.

BioAdaptives, Inc. manufactures and distributes natural, plant- and algae-based products that improve the health and wellness of humans and animals, with a focus on improving pain relief, antiviral activity, and defense of the immune system; stress resistance; Endurance; recovery from injury, illness, and exercise; and anti-aging properties. The company’s current nutritional supplement formulations are carefully selected from the best sources around the world and use proprietary methods to enhance the bioavailability of nutrients. Horse and dog products have also been shown to increase overall health, improve competitive performance, rejuvenating effects, and provide pain relief, as well as provide improvements in appearance. Our current product line includes PrimiLungs™, PrimiCell®, PluriPain® for humans, Canine Regen®, Equine Regen® and Equine All-in-One™ for dogs and horses. Additional human products, to be introduced soon, are designed to aid memory, cognition, and focus; help with sleep and reduce fatigue; Improving overall emotional and physical wellness.

BioAdaptives’ common stock is traded on the OTC market under the symbol BDPT. It has more than 77,000 current shareholders. None of the statements about the company’s products have been approved by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.”

Additional information can be found at or in our SEC files at

Safe Harbor Statement

This press release contains information that constitutes forward-looking statements made in accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis and other information contained in this press release including words such as “expect,” “believe” and “plan” “estimate”, “expects”, “intends” and other similar expressions of opinion constitute forward-looking statements.Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described in the forward-looking statements. Risk factors that could contribute to such differences include those matters that have been fully disclosed in the company’s reports filed with the Securities and Exchange Commission.The forward-looking information contained herein represents the company’s estimates as of the date of the press release, and subsequent events and developments may change the company’s estimates. The Company specifically disclaims any obligation to update forward-looking information in the future.Therefore, such forward-looking information should not be relied upon as representing the Company’s estimates of its future financial performance. Any date later than the date of this press release.


Investor Relations

BioAdaptives, Inc.

(702) 659-8829


More on this topic



Please enter your comment!
Please enter your name here


Popular stories